167 related articles for article (PubMed ID: 21894205)
1. Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.
Lim SH; Johnson PW
Nat Rev Clin Oncol; 2011 Sep; 8(11):634-6. PubMed ID: 21894205
[No Abstract] [Full Text] [Related]
2. Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!
Borchmann P; Engert A; Diehl V
Nat Rev Clin Oncol; 2011 Oct; 8(11):636-7. PubMed ID: 21971592
[No Abstract] [Full Text] [Related]
3. Standard therapy of advanced Hodgkin lymphoma.
Kuruvilla J
Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
Phipps C; Lee YS; Hwang W
Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
[No Abstract] [Full Text] [Related]
5. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
6. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Carde P; Cavalli F; Diehl V; Franklin J
Hematol J; 2000; 1(4):282-90. PubMed ID: 11920203
[No Abstract] [Full Text] [Related]
7. [Treatment of advanced Hodgkin lymphoma].
Kreissl S; Borchmann P
Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
[No Abstract] [Full Text] [Related]
8. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Hodgkin lymphoma: a 50-year perspective.
Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
[No Abstract] [Full Text] [Related]
10. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
11. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
12. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
Gallamini A; Kostakoglu L
Ann Oncol; 2015 Jun; 26(6):1045-1047. PubMed ID: 26003616
[No Abstract] [Full Text] [Related]
13. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for Hodgkin's disease.
Ekert H
N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
[No Abstract] [Full Text] [Related]
15. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
16. ABMT recommended for relapsed Hodgkin's disease, but better overall survival not yet proved.
Oncology (Williston Park); 1996 Apr; 10(4):593-4. PubMed ID: 8723294
[No Abstract] [Full Text] [Related]
17. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
18. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
19. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease.
Ann Oncol; 2001 Sep; 12(9):1213-4. PubMed ID: 11697828
[No Abstract] [Full Text] [Related]
20. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?
Eichenauer DA; Engert A
Leuk Lymphoma; 2009 Nov; 50(11):1733-4. PubMed ID: 19883301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
